Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bordetella pertussis D420 is a clinical isolate of the bacterium that causes whooping cough (pertussis). It is widely used in research and controlled human infection models to study the pathogenesis of pertussis, immune responses, and vaccine efficacy. The strain produces serotype 3 fimbriae and harbors the ptxP3 promoter for pertussis toxin[7][6]. It has been characterized by genomic analysis, including PCR for key virulence genes such as ptxA (subunit A of pertussis toxin), prn (pertactin), and fim2/fim3 (fimbriae types 2 and 3)[7]. The strain is prepared under good laboratory practice conditions for use in challenge studies[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bordetella pertussis d420.